JPRN-UMIN000044278已完成未知
Exploratory study on mechanism of action and immune-related biomarkers in patients with salivary gland cancer who received trastuzumab delxtecan - Exploratory study on mechanism of action and immune-related biomarkers in patients with salivary gland cancer who received trastuzumab delxtecan
Hokkaido University Hospital Medical oncology0 个研究点目标入组 52 人开始时间: 2021年7月31日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •No criteria
研究者
相似试验
尚未招募
2 期
Examinations for immune-biological mechanism of anti-atherosclerotic effects of omega 3 lipid formula, Lotriga, focusing on commensal microbe and serum auto-antibodies.The subjects with hyper-triglyceridemia and atherosclerosis.JPRN-UMIN000032320Yokohama City University Graduate School of Medicine, Department of Medical Science and Cardio-Renal Medicine36
尚未招募
1 期
Study for Immune Molecular Mechanism in the Treatment of Sequelae of Pelvic Inflammatory Disease of Accumulated Damp Heat with Penyanxiao in Combination with Pelvic PerfusioITMCTR2000002965Xianyang Central Hospital
进行中（未招募）
1 期
Mechanistic study assessing the immunological response of subjects after treatment with different formulations of sublingual immunotherapy. - Assessing the immunological response after sublingual immunotherapyEUCTR2006-002123-17-GBImperial College London30
尚未招募
不适用
Research for the Clinical Effect and Immune Mechanism of Soothing the Lung and Anti-fever, Resolving Blood-stasis and Unblocking Collaterals in the Treatment of Mycoplasma Pneumoniae Pneumonia in ChildreMycoplasma Pneumoniae PneumoniaITMCTR1900002294First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
进行中（未招募）
不适用
Study to investigate the immune response to influenza vaccine in patients with multiple sclerosis on teriflunomideMultiple sclerosisMedDRA version: 14.0Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-001160-21-DEsanofi-aventis recherche & developpement120